Results 151 to 160 of about 42,124 (246)

Sustained Hypoxia‐Inducible Factor 1‐Alpha Accumulation Disrupts the Articular Niche to Promote Osteoarthritis Pathogenesis

Aging Cell, Volume 25, Issue 7, July 2026.
Sustained HIF‐1α accumulation is not a compensatory shield, but a potent pathogenic driver of osteoarthritis. Continuous HIF‐1α signaling physically eradicates the avascular cartilage niche and primes the synovium for inflammation, establishing HIF‐1α as a critical target for disease‐modifying therapies.
Weiyuan Gong, Chu Tao, Xingyun Wang, Rongdong Liao, Jianglong Li, Xiongtian Guo, Minghao Qu, Jianmei Huang, Mingjue Chen, Fuxin Wei, Peng Wang, Lijun Lin, Di Chen, Qing Yao, Chunyi Wen, Guozhi Xiao   +15 more
wiley   +1 more source

GLP‐1 Receptors Are Enriched in the Lymphatic Endothelium and Their Pharmacological Activation With Semaglutide Improves the Pumping Capacity of Lymphatic Vessels

Microcirculation, Volume 33, Issue 5, July 2026.
ABSTRACT Objectives Recent clinical studies have suggested that glucagon‐like peptide‐1 receptor (GLP‐1R) agonists may be effective therapies to treat or reduce the risk of developing secondary lymphedema. In this study, we aimed to (1) determine if GLP‐1Rs are present in the lymphatic vasculature and characterize their expression, and (2) assess the ...
Mary E. Schulz, Victoria L. Akerstrom, Joseph H. Dayan, Jorge A. Castorena‐Gonzalez   +3 more
wiley   +1 more source

1,1‐and 1,2‐Diborylalkenes: Preparation and Synthetic Applications

Advanced Synthesis &Catalysis, Volume 368, Issue 12, 17 June 2026.
In this review, we highlight recent advances in the synthesis and reactivity of 1,1‐diborylalkenes and 1,2‐diborylalkenes, along with various transformations leading to C‐C, C‐heteroatom, and multicomponent products. By providing a comprehensive and practical resource, this review aims to assist researchers in exploring the synthetic utility of 1,1 and
Jayaram Vankudoth, Maruti Mali, Fabienne Berrée   +2 more
wiley   +1 more source

Involvement of RFC3 in tamoxifen resistance in ER-positive breast cancer through the cell cycle. [PDF]

Aging (Albany NY), 2023
Zhu J, Ye L, Sun S, Yuan J, Huang J, Zeng Z.   +5 more
europepmc   +1 more source

FOXA2 as a SETD1A-Regulated Driver of Tamoxifen Resistance in Breast Cancer. [PDF]

Oncol Res
Kim MR, Lee JR, Zhang X, Jeong KW.
europepmc   +1 more source

The role of mitochondrial/metabolic axis in development of tamoxifen resistance in breast cancer. [PDF]

Hum Cell, 2023
Azzam HN, El-Derany MO, Wahdan SA, Faheim RM, Helal GK, El-Demerdash E.   +5 more
europepmc   +1 more source

Inhibition of Increased Invasiveness of Breast Cancer Cells With Acquired Tamoxifen Resistance by Suppression of CYR61. [PDF]

Cancer Genomics Proteomics, 2023
Bauerschmitz G, Hüchel S, Gallwas J, Gründker C.   +3 more
europepmc   +1 more source

ASH2L induces tamoxifen resistance via H3K4me3 dependent ITGA6/ERK signaling in ER-positive breast cancer. [PDF]

Br J Cancer
Kye YH, Moon SJ, Cha HR, Kim TH, Eom JY, Myung JK, Kong G.   +6 more
europepmc   +1 more source

ELOVL2-AS1 suppresses tamoxifen resistance by sponging miR-1233-3p in breast cancer. [PDF]

Epigenetics, 2023
Kim HW, Baek M, Jung S, Jang S, Lee H, Yang SH, Kwak BS, Kim SJ.   +7 more
europepmc   +1 more source

Identification of microRNAs associated with tamoxifen resistance in breast cancer

, 2010
Tamoxifen is the most commonly used endocrine therapy for estrogen receptor-positive breast cancer patients. As an estrogen antagonist, tamoxifen competes for binding with estrogen receptor, thereby inhibiting estrogen-dependent gene transcription and ...
Lau, LY, Khoo, US, Chan, KYK
core